| |
Glycosmedia
- weekly publication |
| |
Due to lack of funding Glycosmedia will now
be published weekly. If we can raise sufficient income we will
revert back to a daily publication. We would welcome offers of
advertising, sponsorship or educational grants. Please contact
us for information (Editor) |
| |
|
 |
Insulin
Resistance and Oxidative Stress in Children Born Small and Large
for Gestational Age |
| |
Increased IR and oxidative stress are already
present in prepubertal normal-weight SGA and LGA children with
a continuous alteration in relation to obesity, suggesting that
BW and adiposity represent 2 independent risk factors for degenerative
diseases (Pediatrics) |
| |
|
|
Adverse
cardiovascular events during treatment with pioglitazone and
rosiglitazone: population based cohort study |
| |
Among older patients with diabetes, pioglitazone
is associated with a significantly lower risk of heart failure
and death than is rosiglitazone. Given that rosiglitazone lacks
a distinct clinical advantage over pioglitazone, continued use
of rosiglitazone may not be justified (BMJ) |
| |
|
|
Rosiglitazone
or pioglitazone in type 2 diabetes? |
| |
Longer term safety data are needed before a
change in practice is warranted (Editorial BMJ, UK] |
| |
|
|
Insulin-treated
diabetes in Australia 2000-2007 |
| |
This report shows that the incidence of Type
1 and other insulin-treated diabetes in Australia is increasing
and people with insulin-treated diabetes have significantly higher
death rates than other Australians (AIHW, Australia) |
| |
|
|
Glycemic
Control in Youth with Diabetes: The SEARCH for Diabetes in Youth
Study |
| |
The high percentage of US youth with HbA1c levels
above the target value and with poor glycemic control indicates
an urgent need for effective treatment strategies to improve metabolic
status in youth with diabetes (Journal of Pediatrics) |
| |
|
|
A
cohort study of the risk of cancer associated with type 2 diabetes |
| |
Significantly increased risks were observed
for pancreatic, liver and colon cancer (British Journal of Cancer) |
| |
|
|
Takeda
Reacquires Canadian Rights to Leading Diabetes Drug from Eli
Lilly Canada |
| |
Takeda Canada, Inc. announced that it has reacquired
the Canadian commercial rights to ACTOS(R) (pioglitazone HCl),
an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc.
(BioSpace) |
| |
|
